Firas B Badin, MD - Hematology Oncology ...

Dr. Firas Badin, MD

Claim this profile

Baptist Health Lexington

Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
12 reported clinical trials
23 drugs studied

Area of expertise

1

Lung Cancer

Firas Badin, MD has run 10 trials for Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II
2

Non-Small Cell Lung Cancer

Firas Badin, MD has run 10 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage II

Affiliated Hospitals

Image of trial facility.

Baptist Health Lexington

Image of trial facility.

Baptist Health Floyd

Clinical Trials Firas Badin, MD is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Recruiting

1 award

Phase 2 & 3

13 criteria

More about Firas Badin, MD

Clinical Trial Related

5 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Firas Badin, MD has experience with

  • Carboplatin
  • Pembrolizumab
  • Pemetrexed
  • PD-1 Inhibitor
  • Biospecimen Collection
  • Crizotinib

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Firas Badin, MD specialize in?

Is Firas Badin, MD currently recruiting for clinical trials?

Are there any treatments that Firas Badin, MD has studied deeply?

What is the best way to schedule an appointment with Firas Badin, MD?

What is the office address of Firas Badin, MD?

Is there any support for travel costs?